Restricted accessReview articleFirst published online 2026
Systematic review and meta-analysis of associations between neuropsychiatric symptoms and amyloid,tau,neuronal,and glial biomarkers in young-onset dementias
Neuropsychiatric symptoms (NPS) are highly prevalent in dementia. While biomarkers reflecting amyloid, tau, neuronal injury, and glial activation are increasingly used in dementia research, their association with NPS remains unclear.
Objective
To identify and characterise associations between biomarkers and NPS in people with young-onset dementia (YOD).
Methods
We conducted a systematic review and meta-analysis of studies examining associations between validated biomarkers and NPS in individuals with Alzheimer's disease (AD), frontotemporal dementia (FTD), Huntington's disease (HD), and vascular dementia (VaD), published between 2010 and 2024. The review followed PRISMA guidelines and was prospectively registered (PROSPERO; CRD42022314243).
Results
Principle meta-analyses identified no consistent evidence for associations between NPS and amyloid, tau, and neuronal biomarkers in AD, with limited data available for glial biomarkers. There was a scarcity of studies investigating the relationship between biomarkers and NPS in HD, VaD, and FTD.
Conclusions
The absence of consistent associations likely reflects substantial heterogeneity in pathology, clinical presentation, and methodological approaches, particularly within YOD populations, rather than a true lack of biological linkage. NPS in dementia may emerge from complex bio-psycho-social interactions that transcend classical biomarker models. Longitudinal, multimodal studies are needed to better delineate these relationships.
IsikATSoysalPSolmiM, et al.Bidirectional relationship between caregiver burden and neuropsychiatric symptoms in patients with Alzheimer’s disease: a narrative review. Int J Geriatr Psychiatry2019; 34: 1326–1334.
2.
TerumTMAndersenJRRongveA, et al.The relationship of specific items on the neuropsychiatric inventory to caregiver burden in dementia: a systematic review. Int J Geriatr Psychiatry2017; 32: 703–717.
3.
KitwoodT. The experience of dementia. Aging Mental Health1997; 1: 13–22.
4.
KaufmannEGEngelSA. Dementia and well-being: a conceptual framework based on Tom Kitwood’s model of needs. Dementia2016; 15: 774–788.
5.
SteinbergMShaoHZandiP, et al.Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the cache county study. Int J Geriatr Psychiatry2008; 23: 170–177.
6.
LyketsosCGLopezOJonesB, et al.Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA2002; 288: 1475–1483.
7.
BanerjeeSSmithSCLampingDL, et al.Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. J Neurol Neurosurg Psychiatry2006; 77: 146–148.
8.
OkuraTPlassmanBLSteffensDC, et al.Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc2011; 59: 473–481.
9.
TengELuPHCummingsJL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer’s disease. Dement Geriatr Cogn Disord2007; 24: 253–259.
10.
JackCRJrBennettDABlennowK, et al. NIA-AA Research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement2018; 14: 535–562.
11.
JackCRJrAndrewsJSBeachTG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup. Alzheimers Dement2024; 20: 5143–5169.
12.
TissotCTherriaultJPascoalTA, et al.Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer’s disease. Alzheimers Dement (N Y)2021; 7: e12154.
13.
MoriTShimadaHShinotohH, et al.Apathy correlates with prefrontal amyloid deposition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry2014; 85: 449–455.
14.
GoukasianNHwangKSRomeroT, et al.Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study. BMJ Open2019; 9: e031947.
15.
DangMChenQZhaoX, et al.Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer’s disease. Hum Brain Mapp2023; 44: 327–340.
16.
OvertonMPihlsgårdMElmståhlS. Diagnostic stability of mild cognitive impairment, and predictors of reversion to normal cognitive functioning. Dement Geriatr Cogn Disord2020; 48: 317–329.
17.
BruscoliMLovestoneS. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr2004; 16: 129–140.
18.
MenegonFDe MarchiFAprileD, et al. From mild cognitive impairment to dementia: the impact of comorbid conditions on disease conversion. Biomedicines2024; 12: 1675.
19.
SirkisDWBonhamLWJohnsonTP, et al.Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease. Mol Psychiatry2022; 27: 2674–2688.
20.
GumusMMultaniNMackML, et al.Progression of neuropsychiatric symptoms in young-onset versus late-onset Alzheimer’s disease. GeroScience2021; 43: 213–223.
21.
HendriksSPeetoomKBakkerC, et al.Global incidence of young-onset dementia: a systematic review and meta-analysis. Alzheimers Dement2023; 19: 831–843.
22.
HendriksSPeetoomKBakkerC, et al.Global prevalence of young-onset dementia: a systematic review and meta-analysis. JAMA Neurol2021; 78: 1080–1090.
23.
MocellinRScholesAWalterfangM, et al.Clinical update on frontotemporal dementia: diagnosis and treatment. Australas Psychiatry2015; 23: 481–487.
24.
SantosMAOBezerraLSCorreiaCdC, et al.Neuropsychiatric symptoms in vascular dementia: epidemiologic and clinical aspects. Dement Neuropsychol2018; 12: 40–44.
25.
AnorCJO’ConnorSSaundA, et al.Neuropsychiatric symptoms in Alzheimer disease, vascular dementia, and mixed dementia. Neurodegener Dis2017; 17: 127–134.
26.
LoiSMEratneDGohAMY, et al.A 10 year retrospective cohort study of inpatients with younger-onset dementia. Int J Geriatr Psychiatry2021; 36: 294–301.
27.
VieiraRTCaixetaLMachadoS, et al.Epidemiology of early-onset dementia: a review of the literature. Clin Pract Epidemiol Ment Health2013; 9: 88–95.
28.
Martinez-HortaSPerez-PerezJvan DuijnE, et al.Neuropsychiatric symptoms are very common in premanifest and early stage huntington’s disease. Parkinsonism Relat Disord2016; 25: 58–64.
29.
GohAMWibawaPLoiSM, et al.Huntington’s disease: neuropsychiatric manifestations of Huntington’s disease. Australas Psychiatry2018; 26: 366–375.
30.
KhalilMTeunissenCEOttoM, et al.Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol2018; 14: 577–589.
31.
KhalilMTeunissenCELehmannS, et al.Neurofilaments as biomarkers in neurological disorders — towards clinical application. Nat Rev Neurol2024; 20: 269–287.
32.
ZhaoYXinYMengS, et al.Neurofilament light chain protein in neurodegenerative dementia: a systematic review and network meta-analysis. Neurosci Biobehav Rev2019; 102: 123–138.
33.
AbdelhakAFoschiMAbu-RumeilehS, et al.Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol2022; 18: 158–172.
34.
CarterSFHerholzKRosa-NetoP, et al.Astrocyte biomarkers in Alzheimer’s disease. Trends Mol Med2019; 25: 77–95.
35.
SabatesJChiuW-HLoiS, et al.The associations between neuropsychiatric symptoms and cognition in people with dementia: a systematic review and meta-analysis. Neuropsychol Rev2024; 34: 581–597.
36.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 372: n71.
37.
MorganRLWhaleyPThayerKA, et al.Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environ Int2018; 121: 1027–1031.
38.
HortJO’BrienJTGainottiG, et al.EFNS Guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol2010; 17: 1236–1248.
39.
DuboisBFeldmanHHJacovaC, et al.Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol2010; 9: 1118–1127.
40.
SorbiSHortJErkinjunttiT, et al.EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol2012; 19: 1159–1179.
41.
OlssonBLautnerRAndreassonU, et al.CSF And blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol2016; 15: 673–684.
42.
LuoDWanXLiuJ, et al.Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res2018; 27: 1785–1805.
43.
WanXWangWLiuJ, et al.Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol2014; 14: 135.
44.
HigginsJPTThomasJChandlerJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5 (updated August 2024). Cochrane, www.training.cochrane.org/handbook (2024).
BanningLCPRamakersIHGBDeckersK, et al.Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer’s disease: a systematic literature review. Neurosci Biobehav Rev2019; 107: 346–359.
47.
KangMJYGrewalJEratneD, et al.Neurofilament light and glial fibrillary acidic protein in mood and anxiety disorders: a systematic review and meta-analysis. Brain Behav Immun2025; 123: 1091–1102.
48.
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://wwwR-project org/
49.
ViechtbauerW. Conducting meta-analyses in R with the metafor package. J Stat Softw2010; 36: 1–48.
50.
van AertRCM. Meta-analyzing partial correlation coefficients using fisher’s z transformation. Res Synth Methods2023; 14: 768–773.
51.
WelzTDoeblerPPaulyM. Fisher transformation based confidence intervals of correlations in fixed- and random-effects meta-analysis. Br J Math Stat Psychol2022; 75: 1–22.
52.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
53.
BlonieckiVZetterbergHAarslandD, et al.Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?Alzheimers Res Ther2020; 12: 153.
54.
GabelleAJaussentIHirtzC, et al.Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiol Aging2017; 53: 59–66.
55.
KernDKhalilMPirpamerL, et al.Serum NfL in Alzheimer dementia: results of the prospective dementia registry Austria. Medicina (B Aires)2022; 58: 433.
56.
LiguoriCRomigiANuccetelliM, et al.Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol2014; 71: 1498.
57.
PoulinSPBergeronDDickersonBC, et al.Risk factors, neuroanatomical correlates, and outcome of neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis2017; 60: 483–493.
58.
RobinsonRLRentzDMBruemmerV, et al.Observation of patient and caregiver burden associated with early Alzheimer’s disease in the United States: design and baseline findings of the GERAS-US cohort study. J Alzheimers Dis2019; 72: 279–292.
59.
TargaADakterzadaFBenítezI, et al.Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer’s disease. Sleep2021; 44: zsaa147.
60.
TargaADSBenítezIDDakterzadaF, et al.Sleep profile predicts the cognitive decline of mild-moderate Alzheimer’s disease patients. Sleep2021; 44: zsab117.
61.
VergalloAGiampietriLPagniC, et al.Association between CSF beta-amyloid and apathy in early-stage Alzheimer disease. J Geriatr Psychiatry Neurol2019; 32: 164–169.
62.
WangYLouFLiY, et al.Clinical, neuropsychological, and neuroimaging characteristics of amyloid- positive vs. Amyloid-negative patients with clinically diagnosed Alzheimer’s disease and amnestic mild cognitive impairment. Curr Alzheimer Res2021; 18: 523–532.
63.
HwangYSOhEKimM, et al.Plasma neurofilament light-chain and phosphorylated tau as biomarkers of disease severity in Huntington’s disease: Korean cohort data. J Neurol Sci2023; 452: 120744.
64.
LiX-YGaoBXieJ-J, et al.The clinical, imaging and biological features of psychosis in Han Chinese patients with Huntington’s disease. J Psychiatr Res2021; 141: 333–338.
65.
SampedroFPérez-PérezJMartínez-HortaS, et al.Cortical microstructural correlates of plasma neurofilament light chain in Huntington’s disease. Parkinsonism Relat Disord2021; 85: 91–94.
66.
LeijenaarJFGrootCSudreCH, et al.Comorbid amyloid-β pathology affects clinical and imaging features in VCD. Alzheimers Dement2020; 16: 354–364.
67.
QiaoZWangGZhaoX, et al.Neuropsychological performance is correlated with tau protein deposition and glucose metabolism in patients with Alzheimer’s disease. Front Aging Neurosci2022; 14: 841942.
68.
ArnoldSEXieSXLeungY-Y, et al.Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry2012; 2: e65–e65.
69.
BensamounDGuignardRFurstAJ, et al.Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimers Dis2016; 49: 387–398.
70.
CavaillèsCBerrCHelmerC, et al.Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly. Alzheimers Res Ther2022; 14: 12.
71.
ChungJKPlitmanENakajimaS, et al.Cortical amyloid β deposition and current depressive symptoms in Alzheimer disease and mild cognitive impairment. J Geriatr Psychiatry Neurol2016; 29: 149–159.
72.
DauvilliersYALehmannSJaussentI, et al.Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy. Front Aging Neurosci2014; 6: 119.
73.
De OliveiraFFMiraldoMCDe Castro-NetoEF, et al.Associations of neuropsychiatric features with cerebrospinal fluid biomarkers of amyloidogenesis and neurodegeneration in dementia with Lewy bodies compared with Alzheimer’s disease and cognitively healthy people. J Alzheimers Dis2021; 81: 1295–1309.
74.
HsuJ-LLeeW-JLiaoY-C, et al.The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s disease. Alzheimers Res Ther2017; 9: 91.
75.
LiguoriCChiaravallotiANuccetelliM, et al.Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer’s disease. J Neurol2017; 264: 2215–2223.
76.
LiguoriCSpanettaMIzziF, et al.Sleep-wake cycle in Alzheimer’s disease is associated with tau pathology and orexin dysregulation. J Alzheimers Dis2020; 74: 501–508.
77.
MahdaviMKarimaSRajaeiS, et al.Plasma cytokines profile in subjects with Alzheimer’s disease: interleukin 1 alpha as a candidate for target therapy. Galen Med J2021; 10: e1974.
78.
ScaricamazzaEColonnaISancesarioGM, et al.Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer’s disease patients: a retrospective observational study. Neurol Sci2019; 40: 1377–1382.
79.
TommasiNSGonzalezCBriggsD, et al.Affective symptoms and regional cerebral tau burden in early-stage Alzheimer’s disease. Int J Geriat Psychiatry2021; 36: 1050–1058.
80.
Vinther-JensenTBörnsenLBudtz-JørgensenE, et al.Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm2016; 3: e287.
81.
LiKZengQLuoX, et al.Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer’s disease. Hum Brain Mapp2023; 44: 119–130.
82.
ChenYDangMZhangZ. Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns. Mol Neurodegener2021; 16: 38.
83.
YoungJJBalachandranSGargG, et al.Personality and the risk factors for developing behavioral and psychological symptoms of dementia: a narrative review. Neurodegener Dis Manage2019; 9: 107–118.
84.
Vik-MoAOGiilLMBallardC, et al.Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. Int J Geriatr Psychiatry2018; 33: 1361–1369.
85.
BottoRCallaiNCermelliA, et al.Anxiety and depression in Alzheimer’s disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline. Neurol Sci2022; 43: 4107–4124.
86.
WangXRenPMapstoneM, et al.Identify a shared neural circuit linking multiple neuropsychiatric symptoms with Alzheimer’s pathology. Brain Imaging Behav2019; 13: 53–64.
87.
SampathDSathyanesanMNewtonSS. Cognitive dysfunction in major depression and Alzheimer's disease is associated with hippocampal-prefrontal cortex dysconnectivity. Neuropsychiatr Dis Treat2017; 13: 1509–1519.
88.
ShowrakiAMurariGIsmailZ, et al.Cerebrospinal fluid correlates of neuropsychiatric symptoms in patients with Alzheimer’s disease/mild cognitive impairment: a systematic review. J Alzheimers Dis2019; 71: 477–501.
89.
JusticeNJ. The relationship between stress and Alzheimer’s disease. Neurobiol Stress2018; 8: 127–133.
90.
HsuT-WStubbsBLiangC-S, et al.Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: a systematic review and meta-analysis. Ageing Res Rev2021; 69: 101362.
91.
HenryGWilliamsonDTampiRR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen2011; 26: 169–183.
92.
RobinsonLHutchingsDDickinsonHO, et al.Effectiveness and acceptability of non-pharmacological interventions to reduce wandering in dementia: a systematic review. Int J Geriatr Psychiatry2007; 22: 9–22.
93.
ScalesKZimmermanSMillerSJ. Evidence-based nonpharmacological practices to address behavioral and psychological symptoms of dementia. Gerontologist2018; 58: S88–S102.
94.
ScarioniMGami-PatelPTimarY, et al.Frontotemporal dementia: correlations between psychiatric symptoms and pathology. Ann Neurol2020; 87: 950–961.
95.
RobertPHVerheyFRJByrneEJ, et al.Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry2005; 20: 490–496.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
